MetaCap

Amylyx Pharmaceuticals (AMLX) vs Viridian Therapeutics (VRDN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amylyx Pharmaceuticals (AMLX) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 77.4% versus a loss of 1.3%. Viridian Therapeutics is the larger company by market cap ($3.40 billion vs $3.35 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMLX+77.37%VRDN-1.25%
+182%+57%-67%
Nov 21, 20251 yearNov 20, 2026
AMLX+44.00%VRDN+49.80%
+137%+18%-102%
Jan 3, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMLX versus VRDN key metrics
MetricAMLXVRDN
Share price$26.02$29.96
Market cap$3.35B$3.40B
1-day change-0.69%-4.71%
YTD return+115.40%-3.73%
1-year return+77.37%-1.25%
5-year return—+63.72%
EPS (TTM)$-1.43$-3.85
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$70.85M
Revenue growth (YoY)-100.00%+23359.93%
Net income (latest FY)$-144.74M$-342.60M
Operating margin—-512.91%
Net margin—-483.57%
52-week high$41.14$34.29
52-week low$10.83$13.18
Distance from 52-week high-36.75%-12.63%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+65.26%+42.72%
Average volume1.53M2.14M
Shares outstanding128.56M113.56M
Employees136252
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AMLX has outperformed VRDN by 78.6 percentage points over the past year.
  • Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs -100.00%).

About Amylyx Pharmaceuticals

AMLX stock →

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.

Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees

About Viridian Therapeutics

VRDN stock →

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees

AMLX vs VRDN FAQ

Which is bigger, Amylyx Pharmaceuticals or Viridian Therapeutics?

Viridian Therapeutics (VRDN) is larger, with a market capitalization of $3.40B compared with $3.35B for Amylyx Pharmaceuticals (AMLX).

Which stock has performed better over the past year, AMLX or VRDN?

AMLX returned +77.37% over the past 12 months, compared with -1.25% for VRDN (price return, excluding dividends). Past performance does not predict future results.

Are Amylyx Pharmaceuticals and Viridian Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons